Topics
Glioblastoma | Treatment | Clinical trials | Dendritic-cell-based vaccine
Home > Publications > Topics > Glioblastoma > Treatment > Clinical trials > Dendritic cells
*Sampson JH, Archer GE, Mitchell DA, Heimberger AB, Herndon JE
2nd, Lally-Goss D, McGehee-Norman S, Paolino A, Reardon DA,
Friedman AH, Friedman HS, Bigner DD.
An
epidermal growth factor receptor variant III-targeted vaccine is
safe and immunogenic in patients with glioblastoma multiforme.
Mol
Cancer Ther. 2009 Oct 12;8(10):2773-9. doi:
10.1158/1535-7163.MCT-09-0124. PMID:
19825799. Interventional
study. ˍ
Ridolfi L, Gurrieri L, Riva N, Bulgarelli J, De Rosa F, Guidoboni
M, Fausti V, Ranallo N, Calpona S, Tazzari M, Petrini M, Granato
AM, Pancisi E, Foca F, D'Allagata M, Bondi I, Amadori E, Cortesi
P, Zani C, Ancarani V, Gamboni A, Polselli A, Pasini G, Bartolini
D, Maimone G, Arpa D, Tosatto L.
First
step results from a phase II study of a dendritic cell vaccine in
glioblastoma patients (CombiG-vax).
Front
Immunol. 2024 Aug 13;15:1404861. doi:
10.3389/fimmu.2024.1404861. PMID:
39192978. Interventional study. ˍ
*Wong CE, Chang Y, Chen PW, Huang YT, Chang YC, Chiang CH, Wang
LC, Lee PH, Huang CC, Hsu HJ, Lee JS.
Dendritic
cell vaccine for glioblastoma: an updated meta-analysis and trial
sequential analysis.
J
Neurooncol. 2024 Aug 21. doi:
10.1007/s11060-024-04798-w. PMID:
39167243. Meta-analysis˰
ˍ
Berneman ZN, De Laere M, Germonpré P, Huizing MT, Willemen
Y, Lion E, De Reu H, Van den Bossche J, Van den Brande J,
Specenier P, Altintas S, van Dam PA, Cools N, Nijs G, Stein B,
Caluwaerts K, Snoeckx A, Op de Beeck B, Saevels K, Rutsaert L,
Vandenbosch I, Oner G, Lammens M, Van Damme P, Llewellyn-Lacey S,
Price DA, Oka Y, Oji Y, Sugiyama H, Couttenye MM, Van de Velde AL,
Van Tendeloo VF, Peeters M, Anguille S, Smits ELJM.
WT1-mRNA
dendritic cell vaccination of patients with glioblastoma
multiforme, malignant pleural mesothelioma, metastatic breast
cancer, and other solid tumors: type 1 T-lymphocyte responses are
associated with clinical outcome.
J
Hematol Oncol. 2025 Jan 23;18(1):9. doi:
10.1186/s13045-025-01661-x. PMID:
39849594. Interventional study. ˍ
Bota DA, Piccioni DE, Duma CM, Kesari S, Carrillo JA, LaRocca RV,
Aiken RD, Taylor TH, Abedi M, Robles RM, Godding K, Keirstead HS,
Nistor GI, Dillman RO.
Phase 2 trial
of personal dendritic cell vaccines in newly diagnosed
glioblastoma: 3-year follow-up and correlations with survival.
Hum
Vaccin Immunother. 2025 Sep 12;21(1):2556591. doi:
10.1080/21645515.2025.2556591. PMID:
40938661. Interventional study. ˍ